• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Crinetics Pharmaceuticals Inc (NQ: CRNX )

    54.05 -0.78 (-1.42%)
    Streaming Delayed Price Updated: 11:46 AM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 91,741
    Open 54.08
    Bid (Size) 53.95 (1)
    Ask (Size) 54.10 (4)
    Prev. Close 54.83
    Today's Range 53.60 - 55.01
    52wk Range 15.76 - 55.78
    Shares Outstanding 54,026,103
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
    10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
    Via Benzinga

    Performance

    YTD
    +52.73%
    +52.73%
    1 Month
    +18.37%
    +18.37%
    3 Month
    +22.23%
    +22.23%
    6 Month
    +43.71%
    +43.71%
    1 Year
    +191.53%
    +191.53%

    More News

    Read More
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
    Via Benzinga
    17 Analysts Have This To Say About Crinetics Pharmaceuticals
    Via Benzinga
    18 Analysts Have This To Say About Crinetics Pharmaceuticals
    Via Benzinga
    7 Biotech Stocks to Boost Your Portfolio to Peak Health
    Via InvestorPlace
    EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Crinetics Pharmaceuticals, Inc.
    Via GlobeNewswire
    Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
    Via Benzinga
    Exposures Product Safety
    Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Leading the Way in Tuesday Trading Based on Percentage Gain
    Via Investor Brand Network
    National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.